Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation

NeuroImmunoModulation

Volumn 14, Issue 3-4, 2007, Pages 134-138

  Leceta, Javier ^a   Gomariz, Rosa P ^a   Martinez, Carmen ^a   Carrión, Mar ^a   Arranz, Alicia ^a   Juarranz, Yasmina ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Autoimmunity; T regulatory cells; Th17; Vasoactive intestinal peptide

Indexed keywords

CANCER GROWTH FACTOR; CYTOKINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL FUNCTION; CELL LINEAGE; CONFERENCE PAPER; HELPER CELL; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; INTERLEUKIN-23; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 37049000367     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110636     Document Type: Conference Paper

References (30)

1. Romagnani S: Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225-235.
2. Brombacher F, Kastelein RA, Alber G: Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol 2003;24:207-212.
3. Miyasaka N, Hirata Y: Nitric oxide and inflammatory arthritides. Life Sci 1997;61:2073-2081.
4. Tominaga Y, Nagata M, Yasuda H, Okamoto N, Arisawa K, Moriyama H, Miki M, Yokono K, Kasuga M: Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. Clin Immunol Immunopathol 1998;86:209-218.
5. Shevach EM: Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18:423-449.
6. Kikly K, Liu L, Na S, Sedgwick JD: The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670-675.
7. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J: Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999;93:126-138.
8. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J: Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 2002;80:16-24.
9. Gonzalez-Rey E, Delgado M: Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007;13:241-251.
10. Harrington LE, Mangan PR, Weaver CT: Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006;18:349-356.
11. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
12. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, Czpri M, Milkecz K, Zhang J: IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002;169:3345-3352.
13. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001;7:563-568.
14. Abad C, Juarranz Y, Martinez C, Arranz A, Risignoli F, Garcia-Gomez M, Leceta J, Gomariz RP: cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 2005;11:674-684.
15. Delgado M, Muñoz-Elias EJ, Gomariz RP, Ganea D: VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages: subsequent effect on IFNγ synthesis by T cells. J Neuroimmunol 1999;96:167-181.
16. Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Cañas I, Rosignoli F, Gomariz RP, Leceta J: Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005;7:R1034-R1045.
17. D'Ambrosio D, Panina-Bordignon P, Sinigaglia F: Chemokine receptors in inflammation: an overview. J Immunol Methods 2003;273:3-13.
18. McKenzie BS, Kastelein RA, Cua DJ: Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23.
19. Ishizu T, Osoegawa M, Mei F-J, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J-I: Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128:988-1002.
20. Juarranz MG, Santiago B, Torroba M, Gutierrez-Cañas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL, Gomariz RP: Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 2004;43:416-422.
21. Martinez C, Arranz A, Juarranz Y, Abad C, Garcia-Gomez M, Rosignoli F, Leceta J, Gomariz RP: PAC1 receptor emerging target for septic shock therapy. Ann NY Acad Sci 2006;1070:405-410.
22. Keino H, Kezuka T, Takeuchi M, Yamakawa N, Hattori T, Usui M: Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol 2004;122:1179-1184.
23. Lan YL, Ansari AA, Lian ZX, Gershwin ME: Ragulatory T Cells: development, function and role in immunity. Autoimmune Rev 2005;4:351-363.
24. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M: Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 2005;102:13562-13567.
25. Delgado M, Chorny A, Gonzalez-Rey E, Ganea D: Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukocyte Biol 2005;78:1327-1338.
26. Rosignoli F, Torrroba M, Juarranz Y, Garcia-Gomez M, Martinez C, Gomariz RP, Perez-Leiros C, Leceta J: VIP and tolerance induction in autoimmunity. Ann NY Acad Sci 2006;1070:525-530.
27. Levings MK, Bacchetta R, Schulz U, Roncarolo M-G: The Role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002;129:263-276.
28. Chen W, Jin W, Hardegen N, Lei K-J, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886.
29. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Bäckström BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK: Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007;13:423-431.
30. brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004;6:R335-R346.